Skip to main content
. 2021 Jul 4;10(3):465–494. doi: 10.1007/s40123-021-00365-y
Increasing life expectancy is accompanied by more age-related and chronic posterior eye diseases, which require long-term intervention.
Topical eye drugs must overcome various cellular and liquid barriers to effectively enter the retina from the ocular surface.
Novel topical drugs with innovative formulations have shown encouraging results in improving their permeability and retention time. These formulations include nanospheres, nanocapsules, nanomicelles, nanovesicles, dendrimers, in situ gels, and microneedles.
The rapid and successful clinical translation of novel topical drugs relies on a thorough understanding of the significance and limitations of preclinical models. The emerging in vitro models may provide some valuable information beyond animal models.